Clinical Trials
994 trialsNeoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
IMPACT
University of Florida
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Washington University School of Medicine
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
University of California, San Francisco
ADAGiO
University of Florida
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
University of Michigan Rogel Cancer Center
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
CART123
Children's Hospital of Philadelphia
KOALA
Peter MacCallum Cancer Centre, Australia
NAE-PCOS
Jinnah Sindh Medical University
Study of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia
St. Jude Children's Research Hospital
Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases
M.D. Anderson Cancer Center
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
Memorial Sloan Kettering Cancer Center
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
University of Pennsylvania
CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
University College, London
An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
M.D. Anderson Cancer Center
PIPACOVA
Hospices Civils de Lyon
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy
Yale University
Palbociclib and Pembrolizumab in Sarcoma
University of Iowa
Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia
Beijing GoBroad Hospital
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
City of Hope Medical Center
A Study of Sotorasib in People With Brain Tumors
Memorial Sloan Kettering Cancer Center
Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With Cancer-Related Celiac Pain
Case Comprehensive Cancer Center
DK222 Study at Hopkins
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SABRE
Children's National Research Institute
Therapeutic RSK1 Targeting in Myelofibrosis
Washington University School of Medicine
Catherine
Vall d'Hebron Institute of Oncology
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
M.D. Anderson Cancer Center
LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
M.D. Anderson Cancer Center
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
First-in-Human Assessment of Safety, Biodistribution and Pharmacokinetics of 18F-Fluoro-1-Naphthol (18F-4FN) for PET Imaging
M.D. Anderson Cancer Center
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
Ohio State University Comprehensive Cancer Center
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
FACILITATE
Baptist Health South Florida
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
M.D. Anderson Cancer Center
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
M.D. Anderson Cancer Center
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
St. Jude Children's Research Hospital
PIONEER
University of Utah
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
University of Southern California
Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells
UNC Lineberger Comprehensive Cancer Center
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
M.D. Anderson Cancer Center
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center